Nanobiotix S.A. American Depositary Shares NBTX
i
Market datapartial · fetched 2026-11-06T05:29:22.861Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-05T21:00:00.358883122Z
FundamentalsAlpha Vantage · unavailable
Nanobiotix S.A. American Depositary Shares options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 21.68 | 268.7% | 35.0% | |||
| 25Δ | 24.79 | 203.0% | 24.9% | |||
| 30Δ | 26.17 | 176.9% | 20.5% | |||
| 35Δ | 27.42 | 153.8% | 16.6% | |||
| 40Δ | 28.67 | 130.6% | 12.6% | |||
| 45Δ | 29.92 | 107.5% | 8.6% | |||
| 50Δ | 30.80 | 105.4% | 7.5% | |||
| 55Δ | 29.93 | 107.7% | 8.3% | 31.65 | 104.6% | 6.5% |
| 60Δ | 29.04 | 108.8% | 7.3% | 32.50 | 103.8% | 5.5% |
| 65Δ | 28.15 | 109.9% | 6.2% | 33.35 | 103.0% | 4.5% |
| 70Δ | 27.25 | 110.9% | 5.1% | 34.20 | 102.3% | 3.5% |
| 75Δ | 26.36 | 112.0% | 4.1% | 35.11 | 101.7% | 2.5% |
| 80Δ | 25.47 | 113.0% | 3.0% | 36.94 | 104.6% | 1.9% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 21.68
- IV
- 268.7%
- B/E move
- 35.0%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 24.79
- IV
- 203.0%
- B/E move
- 24.9%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 26.17
- IV
- 176.9%
- B/E move
- 20.5%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 27.42
- IV
- 153.8%
- B/E move
- 16.6%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 28.67
- IV
- 130.6%
- B/E move
- 12.6%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 29.92
- IV
- 107.5%
- B/E move
- 8.6%
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 30.80
- IV
- 105.4%
- B/E move
- 7.5%
55Δ
- Pseudo strike
- 29.93
- IV
- 107.7%
- B/E move
- 8.3%
- Pseudo strike
- 31.65
- IV
- 104.6%
- B/E move
- 6.5%
60Δ
- Pseudo strike
- 29.04
- IV
- 108.8%
- B/E move
- 7.3%
- Pseudo strike
- 32.50
- IV
- 103.8%
- B/E move
- 5.5%
65Δ
- Pseudo strike
- 28.15
- IV
- 109.9%
- B/E move
- 6.2%
- Pseudo strike
- 33.35
- IV
- 103.0%
- B/E move
- 4.5%
70Δ
- Pseudo strike
- 27.25
- IV
- 110.9%
- B/E move
- 5.1%
- Pseudo strike
- 34.20
- IV
- 102.3%
- B/E move
- 3.5%
75Δ
- Pseudo strike
- 26.36
- IV
- 112.0%
- B/E move
- 4.1%
- Pseudo strike
- 35.11
- IV
- 101.7%
- B/E move
- 2.5%
80Δ
- Pseudo strike
- 25.47
- IV
- 113.0%
- B/E move
- 3.0%
- Pseudo strike
- 36.94
- IV
- 104.6%
- B/E move
- 1.9%
Options history
Table
| Date | IV (%) |
|---|---|
| 82.45% | |
| 74.01% | |
| 83.99% | |
| 84.40% | |
| 86.00% |
Biotechnology
NGNE
Neurogene Inc. is an innovative biotechnology company at the forefront of developing advanced gene therapies for rare neurological disorders, addressing significant unmet medical…
More →NKTR
Nektar Therapeutics is a biopharmaceutical company. The company is headquartered in San Francisco, California with additional operations in Huntsville, Alabama and Hyderabad,…
More →NKTX
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and markets cell therapies for the treatment of cancer. The company is headquartered in South San Francisco,…
More →NMRA
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and…
More →NRIX
Description unavailable
More →NRXP
NRx Pharmaceuticals, Inc., a clinical-stage small molecule pharmaceutical company, develops new treatments for the treatment of life-threatening central nervous system disorders…
More →